Meprobamate is a prescription medication used primarily for the short-term relief of anxiety symptoms and treatment of anxiety disorders. It belongs to the class of drugs known as anxiolytics or anti-anxiety agents and was first introduced in the 1950s under the brand name
Miltown.
Meprobamate is a carbamate derivative and acts as a central nervous system (CNS) depressant, helping to calm the brain and reduce feelings of nervousness, tension, and anxiety. Sources:
Meprobamate exerts its anxiolytic effects by interacting with the gamma-aminobutyric acid (GABA) receptors in the brain. GABA is an inhibitory neurotransmitter that helps to calm the nervous system by reducing the excitability of nerve cells.
Meprobamate enhances the effects of GABA, leading to a decrease in anxiety, muscle tension, and overall CNS activity. Sources: The primary therapeutic use of meprobamate is for the short-term relief of anxiety symptoms and treatment of anxiety disorders, such as generalized anxiety disorder (GAD), panic disorder, and social anxiety disorder. It may also be used off-label for other conditions, such as
alcohol withdrawal, muscle spasms, and insomnia, although its efficacy in these cases is not well-established. Sources:
Meprobamate was originally marketed by Wallace Laboratories under the brand name
Miltown in 1955. It was later sold under various other brand names, such as
Equanil by Wyeth. However, due to concerns over its potential for abuse and dependence, meprobamate is no longer widely marketed or prescribed, and many of its brand names have been discontinued. Sources:
Meprobamate is typically administered orally in the form of tablets or capsules. The recommended dosage for adults is typically between 400 and 800 mg per day, divided into multiple smaller doses. For children aged 6 years and older, the recommended dosage is lower, typically 200 to 400 mg per day, divided into smaller doses. Sources: Common side effects associated with meprobamate use include drowsiness, dizziness, headache, nausea, and vomiting. More severe adverse reactions may include confusion, slurred speech, irregular heartbeat, and respiratory depression. Long-term use of meprobamate can lead to physical and psychological dependence, tolerance, and withdrawal symptoms upon discontinuation. Sources:
Meprobamate is contraindicated in individuals with known hypersensitivity or allergy to the drug, severe respiratory impairment, or acute alcohol intoxication. It should be used with caution in patients with impaired renal or hepatic function, as well as in the elderly and pregnant women.
Meprobamate may interact with other CNS depressants, such as alcohol, opioids, and barbiturates, potentiating their effects and increasing the risk of respiratory depression. Sources:
Meprobamate is well absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within 2 to 4 hours after oral administration. It is widely distributed throughout the body and is metabolized primarily in the liver via hydroxylation and conjugation. The elimination half-life of meprobamate ranges from 6 to 17 hours, with the metabolites being excreted primarily in the urine. Sources: Compared to other anxiolytic drugs, such as benzodiazepines, meprobamate has a slower onset of action and longer duration of effects. While it may be effective in managing anxiety symptoms, meprobamate has a higher risk of dependence and more severe withdrawal symptoms than benzodiazepines. Additionally, benzodiazepines are generally considered safer and have a more favorable safety profile than meprobamate. Sources:
Meprobamate was first introduced in the 1950s and quickly gained popularity as a treatment for anxiety and nervousness, becoming one of the first widely prescribed psychotropic drugs. However, concerns over its potential for abuse and dependence led to a decline in its use, and it was eventually replaced by newer, safer anxiolytic medications such as benzodiazepines. Today, meprobamate is rarely prescribed and is considered a controlled substance in many countries. Sources: In addition to its anxiolytic effects, meprobamate exhibits anticonvulsant, muscle relaxant, and sedative properties. It has been studied for its potential use in the treatment of epilepsy, muscle spasms, and insomnia, although its efficacy in these areas is not well-established.
Meprobamate is also known to have a shorter duration of action compared to other carbamate derivatives. Sources: While meprobamate is not widely used in clinical practice today, ongoing research continues to explore its potential applications and mechanisms of action. Some recent studies have investigated the use of meprobamate in combination with other medications for the treatment of
alcohol withdrawal syndrome and as an adjunctive therapy for certain types of seizures. Additionally, researchers are investigating the potential role of meprobamate in modulating the endocannabinoid system, which may have implications for its anxiolytic and other effects. Sources: Patients taking meprobamate should be closely monitored by their healthcare provider for signs of dependence, tolerance, or adverse reactions. It is important to follow dosage instructions carefully and not to abruptly discontinue the medication, as this can lead to withdrawal symptoms. Patients should also be advised to avoid activities that require alertness or coordination until they understand how the medication affects them. Regular follow-up appointments and open communication with the prescribing physician are essential for safe and effective use of meprobamate. Sources:
Meprobamate: Uses, Dosage, Side Effects, and More
Table of Contents
Introduction to
Meprobamate
Pharmacodynamics and Mechanism of Action
Therapeutic Uses
Brand Names and Marketing
Dosing and Administration
Side Effects and Adverse Reactions
Warnings and Precautions
Pharmacokinetics
Comparative Analysis
Historical Context and
Epidemiology
Miscellaneous Properties
Research and Future Directions
Patient Considerations
